Home > Insider Trading > Filing (0000899243-22-038538)

Filing Details

Accession Number:: 0000899243-22-038538
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-12-14 21:50:16
Reporting Period:: 2022-12-12

Accepted Time:: 2022-12-14 21:50:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786322	Giuseppe Ciaramella	C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142	President & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-12-12	18,211	$0.67	133,825	No	4	M	Direct
Common Stock	Acquisiton	2022-12-12	8,652	$4.22	142,477	No	4	M	Direct
Common Stock	Disposition	2022-12-12	31,699	$42.30	110,778	No	4	S	Direct
Common Stock	Disposition	2022-12-12	13,933	$43.15	96,845	No	4	S	Direct
Common Stock	Disposition	2022-12-12	5,383	$43.87	91,462	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-12-12	18,211	$0.00	18,211	$0.67
Common Stock	Stock Option (Right to Buy)	Disposition	2022-12-12	8,652	$0.00	8,652	$4.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
189,491		2028-05-08	No	4	M	Direct
4,326		2029-02-13	No	4	M	Direct

Footnotes

The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $42.71, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.76 to $43.75, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.76 to $44.06, inclusive.
25% of the shares subject to the stock option vested on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.
The option award vests upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.